Accession Number : ADA551902


Title :   University of Washington Prostate Cancer Clinical Trials Consortium Application


Descriptive Note : Annual rept. 1 Apr 2010-31 Mar 2011


Corporate Author : WASHINGTON UNIV SEATTLE


Personal Author(s) : Higano, Celestia


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a551902.pdf


Report Date : Apr 2011


Pagination or Media Count : 36


Abstract : Purpose: Maintain active and productive status as a member of the Prostate Cancer Clinical Trails Consortium throughout the funding period. Scope: Since the annual report of April 2010, the University of Washington continues to be an active contributing member of the PCCTC, fulfilling goals set forth in the Statement of Work. Major Progress: This last year, we opened 3 trials, and introduced 3 Letters of Intent (LOIs) to the Consortium. We are opening 5 additional therapeutic trials and have agreed to participate in 2 additional trails. We enrolled 42 patients on therapeutic trials and 7 patients on Consortium biomarker validation (phase 3) trials. We are authors on 9 Consortium abstracts, and 2 manuscripts, (all abstracts presented or to be presented at ASCO, AUA, GU ASCO). An active plan to recruit minority/disproportionately affected populations is a high priority and therefore in constant evolution. Our recruitment in this area matches the regional proportion of these populations. Results: We continue to develop and grow our infrastructure that supports active, productive Consortium participation and which has enabled us to reach the stated goals for patient accrual and LOI proposals. Significance: The Consortium provides a mechanism for participation in early clinical development of novel agents and rapid testing of these agents for the treatment of prostate cancer. At our institution, our scientific/SPORE/PCF Challenge grant and Consortium clinical research goals are complementary. Validation of biomarkers is of great significance for shortening the time to drug approval and availability of new agents to patients with prostate cancer.


Descriptors :   *CLINICAL TRIALS , *PROSTATE CANCER , CHEMOTHERAPEUTIC AGENTS , CHEMOTHERAPY , CLINICAL MEDICINE , MEDICAL RESEARCH , MINORITIES , PATIENTS


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE